Healthcare Industry News: Guided Therapeutics
News Release - January 23, 2012
Cerulean Pharma Appoints Chief Business OfficerChris Guiffre named to the newly created position to help lead business development and partnering activities
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)-- Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the appointment of Chris Guiffre as Senior Vice President and Chief Business Officer, a newly created position.
Mr. Guiffre most recently served as President and Chief Executive Officer of Alvos Therapeutics, Inc., a biopharmaceutical company dedicated to developing "Guided Therapeutics" that destroy cancer cells while sparing normal tissues. Previously, Mr. Guiffre was Chief Business Officer at Hydra Biosciences, Inc., and he was formerly Senior Vice President, General Counsel and Secretary at Cubist Pharmaceuticals, Inc. Prior to Cubist, Mr. Guiffre held positions of increasing responsibility, including Vice President, General Counsel and Clerk, at Renaissance Worldwide, Inc. He earned a B.S. from Babson College, a J.D. from Boston College Law School, and an M.B.A. from Boston College Carroll School of Management.
“We are pleased to have Chris join Cerulean and lead our business development and partnering activities at an exciting time in our corporate evolution,” said Oliver Fetzer, Ph.D., President and Chief Executive Officer of Cerulean. “Chris is a seasoned pharmaceutical executive, and his wealth of business and transactional experience will be highly valuable as Cerulean accelerates its corporate development activities in 2012 and beyond.”
About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company’s technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company’s website at http://www.ceruleanrx.com.
Source: Cerulean Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.